IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
摘要
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
申请公布号
WO2008151088(A3)
申请公布日期
2009.04.02
申请号
WO2008US65428
申请日期
2008.05.30
申请人
UNIVERSITY OF MARYLAND, BALTIMORE;STROME, SCOTT E.;SCHULZE, DAN H.;BLOCK, DAVID S.